Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

NCT01336465 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01336465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
June 30, 2013
Enrollment
124 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis